证券代码：000516 证券简称：国际医学 编号：2023-02 西安国际医学投资股份有限公司投资者关系活动记录表 | | 特定对象调研 □分析师会议 □媒体采访 业绩说明会 | | --- | --- | | |  | | 投资者关系活动 | □新闻发布会 路演活动 | | 类别 | 现场参观 | | | 其他_____ | | 参与单位名称及 | 天风证券杨松、李慧瑶，中信证券沈睦钧、张佳绘，国盛证券胡偌碧、王 | | 人员姓名 | 光华、宋歌、胡婧怡、齐德仪，兴业证券东楠，开源证券蔡明子、古意涵， | | | 申万宏源证券张静含、余玉君、陈田甜，广发证券陈明、王少喆、方程嫣， | | | 东北证券刘宇腾、叶菁、孙维泽，海通证券梁广楷，西部证券陆伏崴、陈 | | | 嘉烨，中信建投证券刘岚，安信证券贺鑫、马正南，光大证券刘勇、吴佳 | | | 青，东吴证券冉胜男，国都证券文惠霞，华安证券谭国超、陈珈蔚，平安 | | | 证券李颖睿，国信证券李茗欣、贺平鸽，国联证券安柯，国融宗楚昀，东 | | | 兴证券刘春胜，东亚前海证券孙洁玲、都成，华泰证券孙茗馨，首创证券 | | | 陈宇，华金证券周平、吴 ...

Financial Performance - Total assets increased by 1.48% to RMB 13,460,535,622.49 compared to the adjusted figure of RMB 13,264,224,493.51[6] - Equity attributable to shareholders of the listed company decreased by 1.55% to RMB 4,184,794,966.92 from the adjusted figure of RMB 4,250,695,185.16[6] - Net profit for the period was RMB -95,739,550.26, compared to RMB -432,820,830.09 in the same period last year[10] - Diluted earnings per share were RMB -0.0291, compared to RMB -0.1882 in the same period last year[10] - The company achieved a revenue of 1,059.09 million yuan in Q1 2023, a year-on-year increase of 247.40%[22] - Net profit attributable to the parent company in Q1 2023 was -74.74 million yuan, a year-on-year increase of 82.55%[22] - Total operating revenue for the current period is RMB 1,059,092,457.42, a significant increase from RMB 304,865,465.75 in the previous period[30] - Net profit attributable to the parent company's owners is RMB -74,740,547.17, compared to RMB -428,421,595.49 in the previous period[45] - Basic earnings per share for the current period is RMB -0.0328, an improvement from RMB -0.1882 in the previous period[45] - Revenue for the reporting period was 1,059,092,457.42 yuan, a 247.40% increase year-over-year[52] - Net profit attributable to shareholders improved to -74,740,547.17 yuan, an 82.55% improvement compared to the same period last year[52] - Basic earnings per share improved to -0.0328 yuan, an 82.57% increase compared to the same period last year[52] - Weighted average return on equity improved to -1.75%, a 6.59 percentage point increase from the same period last year[52] Operating Costs and Expenses - Operating costs increased by 78.92% year-on-year due to the new medical campuses and business expansion of the medical subsidiaries[9] - Taxes and surcharges increased by 151.05% year-on-year, mainly due to increased property tax provisions by the subsidiary Xi'an International Medical Center Co., Ltd.[9] - Operating costs for the current period are RMB 972,385,400.75, up from RMB 543,474,761.78 in the previous period[30] - R&D expenses for the current period are RMB 3,325,497.80, up from RMB 2,358,282.37 in the previous period[30] - Taxes and fees paid increased to 17,689,687.01 yuan, up from 12,038,564.57 yuan in the same period last year[47] - Employee compensation and benefits paid were 398,160,903.03 yuan, slightly higher than the previous year's 392,733,192.48 yuan[47] Cash Flow - Net cash flow from operating activities increased by 208.07% year-on-year due to significant revenue growth from medical subsidiaries[9] - Net cash flow from financing activities increased by 565.41% year-on-year due to increased cash received from loans by the company and its subsidiaries[9] - Cash received from selling goods and providing services is RMB 804,974,363.77, up from RMB 350,233,145.31 in the previous period[45] - Operating cash flow increased significantly to 222,931,373.21 yuan, a 208.07% increase compared to the same period last year[52] - Net cash flow from financing activities was 130,029,914.30 yuan, compared to -27,939,026.41 yuan in the same period last year[48] - Cash and cash equivalents decreased by 2,154,077.89 yuan, ending the period at 1,181,624,032.36 yuan[48] - Investment cash outflow was 379,185,244.06 yuan, primarily for fixed assets and long-term investments[47] Asset and Liability Changes - Accounts receivable increased by 39.85% compared to the end of the previous year, mainly due to increased medical insurance settlement receivables[22] - Prepayments increased by 151.28% compared to the end of the previous year, mainly due to increased prepaid operating expenses[22] - Other current assets increased by 30.35% compared to the end of the previous year, mainly due to increased deductible input tax[22] - Fixed assets increased by 40.49% compared to the end of the previous year, while construction in progress decreased by 96.34%, mainly due to the transfer of completed projects to fixed assets[22] - Other non-current assets increased by 32.50% compared to the end of the previous year, mainly due to increased prepayments for equipment[22] - Minority interests decreased by 17,655.36% compared to the end of the previous year, mainly due to reduced minority interest losses[22] - Total current liabilities amounted to 5,744.59 million yuan, while total non-current liabilities amounted to 3,552.03 million yuan[15] - Total liabilities and owner's equity amounted to 13,460.54 million yuan[15] - Total assets at the end of the period are RMB 13,460,535,622.49, slightly higher than RMB 13,264,224,493.51 at the beginning of the period[41] - Fixed assets at the end of the period are RMB 7,986,846,562.55, a significant increase from RMB 5,684,908,536.84 at the beginning of the period[41] - Total current assets at the end of the period are RMB 3,915,116,034.38, compared to RMB 3,711,899,394.23 at the beginning of the period[41] - Total non-current assets at the end of the period are RMB 9,545,419,588.11, slightly lower than RMB 9,552,325,099.28 at the beginning of the period[41] Investment and Fair Value Changes - Investment income decreased by 98.30% year-on-year due to reduced financial product income[9] - Fair value change income increased by 210.03% year-on-year due to increased fair value change income from held trading financial assets[9]

西安国际医学投资股份有限公司 年年度报告 2022 ...

证券代码：000516 证券简称：国际医学 编号：2015-06 西安国际医学投资股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|---------------------------------------------------------| | | | | | | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 _________ | | | 参与单位名称及 | | 西南证券 何治力、张婷；长城证券 赵浩然；太平洋证券 祝琳 | | 人员姓名 | | 琪；华创证券 邱旻；信达证券 吴临平；中海基金 郑辰；野风 | | | | 资产管理 于波；中邮基金 李晨；摩根士丹利华鑫基金 缪东 | | | 丁天宇等 | 航；中欧瑞博 张宪强；广发基金 王瑞冬；中国人寿资产管理 | | 时间 | 2015 年 08 月 13 | 日 | | 地点 | ...

证券代码：000516 证券简称：国际医学 编号：2015-04 西安国际医学投资股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------------| | | | | | | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 _________ | | | 参与单位名称及 | | 申万宏源证券 周波；国信证券 邓周宇；国海证券 陈铁林；财 | | 人员姓名 | | 富证券 汤佩徽；中欧基金 黄盼盼；国联安基金 焦阳；光大永 | | | | 明资产 孙伟娜；华宝兴业基金 夏林锋；南山资本 李思婷；五 | | | | 矿资本 周智；九沐资本 胡建伟等。 | | 时间 | 2015 年 04 月 29 | 日 | | 地点 | 国际医学会议室 | ...